Formosa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Formosa Pharmaceuticals's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 64.8% per year.
Key information
-3.6%
Earnings growth rate
10.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 64.8% |
| Return on equity | -12.8% |
| Net Margin | -149.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Formosa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 137 | -205 | 62 | 255 |
| 30 Jun 24 | 134 | -303 | 60 | 287 |
| 31 Mar 24 | 82 | -312 | 50 | 279 |
| 31 Dec 23 | 31 | -322 | 40 | 270 |
| 30 Sep 23 | 31 | -378 | 36 | 312 |
| 30 Jun 23 | 32 | -339 | 33 | 321 |
| 31 Mar 23 | 16 | -372 | 29 | 339 |
| 31 Dec 22 | 1 | -406 | 26 | 356 |
| 30 Sep 22 | 1 | -416 | 25 | 368 |
| 30 Jun 22 | 1 | -419 | 22 | 392 |
| 31 Mar 22 | 15 | -410 | 22 | 390 |
| 31 Dec 21 | 29 | -401 | 21 | 388 |
| 30 Sep 21 | 28 | -346 | 21 | 334 |
| 30 Jun 21 | 28 | -290 | 21 | 281 |
| 31 Mar 21 | 14 | -255 | 19 | 249 |
| 31 Dec 20 | 0 | -220 | 17 | 216 |
| 31 Dec 19 | 1 | -197 | 8 | 191 |
Quality Earnings: 6838 is currently unprofitable.
Growing Profit Margin: 6838 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6838 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 6838's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6838 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).
Return on Equity
High ROE: 6838 has a negative Return on Equity (-12.78%), as it is currently unprofitable.